companiesCompany
ESSA Pharma
ESSA Pharma developed masofaniten, an AR N-terminal-domain inhibitor whose phase 2 was stopped for futility in 2024-25.
Masofaniten (EPI-7386) + enzalutamide phase 2 in mCRPC terminated after a futility analysis (PSA90 endpoint); development discontinued and strategic options under review. An instructive failure for the AR-NTD concept.
Pages like this
not linked directly; found by shared links- TermAR-V7 splice variant
Shares Masofaniten, Prostate cancer.
- TargetAndrogen receptor
Shares Masofaniten, Prostate cancer.